A preliminary randomized double¨Cblind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive¨Ccompulsive disorder

详细信息    查看全文

• 作者：Mehdi Sayyah^a ;   ; ^{sayah_bargard@Hotmail.com} ; Hatam Boostani^b ; Siroos Pakseresht^b ; Alireza Malayeri^c
• 关键词：Obsessive&ndash ; compulsive disorder ; Celecoxib ; COX-2 inhibitors
• 刊名：Psychiatry Research
• 出版年：2011
• 出版时间：30 October 2011
• 年：2011
• 卷：189
• 期：3
• 页码：403-406
• 全文大小：278 K

文摘

Obsessive¨Ccompulsive disorder is a common neuropsychiatric condition. Although a variety of pharmaceutical agents is available for its treatment, psychiatrists have found that many patients cannot tolerate the side effects, do not respond to treatment adequately, and may finally discontinue their treatment. However, augmentation strategies have been shown to have some benefits in the treatment of OCD. These include reducing both the overall cost of treatment and the side effects. The purpose of this study was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of OCD in an 8-week, double-blind, placebo controlled trial. To this end, 25 patients were assigned to a study group and were given fluoxetine 20 mg/day plus celecoxib 400 mg/day (200 mg BID). The control group included 25 patients who were given fluoxetine 20 mg/day plus placebo. Both protocols significantly lowered scores on the Yale-Brown Obsessive-Compulsive Scale over the trial period. The combination of fluoxetine and celecoxib decreased the symptoms of obsessions and compulsions significantly more than fluoxetine plus placebo. The results of this study suggest that celecoxib can be an effective adjuvant agent in the management of patients with OCD; therefore, anti-inflammatory therapies should be further investigated.